Verastem Net Worth
Verastem Net Worth Breakdown | VSTM |
Verastem Net Worth Analysis
Verastem's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Verastem's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Verastem's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Verastem's net worth analysis. One common approach is to calculate Verastem's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Verastem's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Verastem's net worth. This approach calculates the present value of Verastem's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Verastem's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Verastem's net worth. This involves comparing Verastem's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Verastem's net worth relative to its peers.
Enterprise Value |
|
To determine if Verastem is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Verastem's net worth research are outlined below:
| Verastem is way too risky over 90 days horizon | |
| Verastem appears to be risky and price may revert if volatility continues | |
| Verastem has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (87.37 M) with profit before overhead, payroll, taxes, and interest of 2.6 M. | |
| Verastem currently holds about 94.31 M in cash with (86.46 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.5. | |
| Verastem has a frail financial position based on the latest SEC disclosures | |
| Roughly 60.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Disposition of 3245 shares by Paterson Dan of Verastem at 2.16 subject to Rule 16b-3 |
Verastem uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Verastem. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Verastem's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 12th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 12th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Verastem's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Verastem is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Verastem backward and forwards among themselves. Verastem's institutional investor refers to the entity that pools money to purchase Verastem's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Ubs O'connor Llc | 2024-09-30 | 430.7 K | Affinity Asset Advisors, Llc | 2024-09-30 | 400 K | State Street Corp | 2024-06-30 | 359 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 332.4 K | Northern Trust Corp | 2024-09-30 | 286.6 K | Tang Capital Management Llc | 2024-09-30 | 270 K | Sio Capital Management, Llc | 2024-09-30 | 133.4 K | Dafna Capital Management Llc | 2024-09-30 | 127.7 K | Charles Schwab Investment Management Inc | 2024-09-30 | 103.6 K | Nantahala Capital Management, Llc | 2024-09-30 | 3.7 M | Vanguard Group Inc | 2024-09-30 | 1.9 M |
Follow Verastem's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 203.39 M.Market Cap |
|
Project Verastem's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.58) | (0.61) | |
| Return On Capital Employed | (0.75) | (0.78) | |
| Return On Assets | (0.58) | (0.61) | |
| Return On Equity | (1.52) | (1.60) |
When accessing Verastem's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Verastem's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Verastem's profitability and make more informed investment decisions.
Evaluate Verastem's management efficiency
Verastem has return on total asset (ROA) of (0.4731) % which means that it has lost $0.4731 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.3687) %, meaning that it created substantial loss on money invested by shareholders. Verastem's management efficiency ratios could be used to measure how well Verastem manages its routine affairs as well as how well it operates its assets and liabilities. As of the 29th of November 2024, Return On Tangible Assets is likely to drop to -0.61. In addition to that, Return On Capital Employed is likely to drop to -0.78. At this time, Verastem's Other Current Assets are very stable compared to the past year. As of the 29th of November 2024, Non Current Assets Total is likely to grow to about 11.4 M, while Non Currrent Assets Other are likely to drop about 4.2 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 3.56 | 3.38 | |
| Tangible Book Value Per Share | 3.56 | 3.38 | |
| Enterprise Value Over EBITDA | (1.71) | (1.80) | |
| Price Book Value Ratio | 3.13 | 3.29 | |
| Enterprise Value Multiple | (1.71) | (1.80) | |
| Price Fair Value | 3.13 | 3.29 | |
| Enterprise Value | 34 M | 32.3 M |
Understanding the operational decisions made by Verastem management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Enterprise Value Revenue 15.2809 | Revenue 10 M | Quarterly Revenue Growth (1.00) | Revenue Per Share 0.331 | Return On Equity (1.37) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Verastem insiders, such as employees or executives, is commonly permitted as long as it does not rely on Verastem's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Verastem insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Verastem Corporate Filings
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
13A | 8th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
F4 | 7th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10Q | 6th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
Verastem Earnings per Share Projection vs Actual
Verastem Corporate Management
| Jonathan Pachter | Chief Officer | Profile | |
| Michael Crowther | Chief Officer | Profile | |
| Sean Flynn | Gen VP | Profile | |
| MD MSc | Head Strategy | Profile | |
| Robert Weinberg | CoFounder Board | Profile | |
| Daniel Calkins | Interim Officer | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Verastem. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in Verastem Stock, please use our How to Invest in Verastem guide.You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Verastem. If investors know Verastem will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Verastem listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.14) | Revenue Per Share 0.331 | Quarterly Revenue Growth (1.00) | Return On Assets (0.47) | Return On Equity (1.37) |
The market value of Verastem is measured differently than its book value, which is the value of Verastem that is recorded on the company's balance sheet. Investors also form their own opinion of Verastem's value that differs from its market value or its book value, called intrinsic value, which is Verastem's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Verastem's market value can be influenced by many factors that don't directly affect Verastem's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Verastem's value and its price as these two are different measures arrived at by different means. Investors typically determine if Verastem is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Verastem's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.